Liao Wen-Ling, Chang Chiz-Tzung, Chen Ching-Chu, Lee Wen-Jane, Lin Shih-Yi, Liao Hsin-Yi, Wu Chia-Ming, Chang Ya-Wen, Chen Chao-Jung, Tsai Fuu-Jen
Graduate Institute of Integrated Medicine, China Medical University, Taichung 404, Taiwan.
Center for Personalized Medicine, China Medical University Hospital, Taichung 404, Taiwan.
J Clin Med. 2018 Nov 26;7(12):483. doi: 10.3390/jcm7120483.
Diabetic nephropathy (DN) is a major complication in diabetic patients. Microalbuminuria testing is used to identify renal disease; however, its predictive value is questionable. We aimed to identify urinary biomarkers to early diagnosis nephropathy before identifiable alternations in kidney function or urine albumin excretion occurs. Proteomic approaches were used to identify potential urinary biomarkers and enzyme-linked immunosorbent assay was performed to verify the results. The data identified haptoglobin (HPT) and α-1-microglobulin/bikunin precursor (AMBP) as two biomarkers with the highest ability to distinguish between healthy individuals and patients with nephropathy, and between diabetic patients with and without DN. Further, the HPT-to-creatinine ratio (HCR) was evaluated as an independent predictor of early renal functional decline (ERFD) in a cohort with an average follow-up of 4.2 years. The area under the curve (AUC) value for ERFD prediction was significantly improved when the HCR biomarker was included in the model with albumin to creatinine ratio (ACR) and baseline characteristics (AUC values were 0.803 and 0.759 for HCR and ACR, respectively; value was 0.0423 for difference between models). In conclusion, our results suggest that HCR represents an early indicator of nephropathy, and a marker related to ERFD among diabetic patients in Taiwan.
糖尿病肾病(DN)是糖尿病患者的主要并发症。微量白蛋白尿检测用于识别肾脏疾病;然而,其预测价值存在疑问。我们旨在识别尿生物标志物,以便在肾功能或尿白蛋白排泄出现可识别变化之前早期诊断肾病。采用蛋白质组学方法识别潜在的尿生物标志物,并进行酶联免疫吸附测定以验证结果。数据确定触珠蛋白(HPT)和α-1-微球蛋白/比 Kunin 前体(AMBP)是区分健康个体与肾病患者以及糖尿病肾病患者与非糖尿病肾病患者能力最强的两种生物标志物。此外,在平均随访 4.2 年的队列中,评估了 HPT 与肌酐比值(HCR)作为早期肾功能下降(ERFD)的独立预测指标。当将 HCR 生物标志物纳入包含白蛋白与肌酐比值(ACR)和基线特征的模型时,ERFD 预测的曲线下面积(AUC)值显著提高(HCR 和 ACR 的 AUC 值分别为 0.803 和 0.759;模型间差异的 P 值为 0.0423)。总之,我们的结果表明,HCR 代表肾病的早期指标,并且是台湾糖尿病患者中与 ERFD 相关的标志物。